Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury

• Main Authors: Chong Liu (Author), Yong Liu (Author), Jing He (Author), Rong Mu (Author), Yanbo Di (Author), Na Shen (Author), Xuan Liu (Author), Xiao Gao (Author), Jinhui Wang (Author), Tie Chen (Author), Tao Fang (Author), Huanming Li (Author), Fengshi Tian (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Liraglutide (Lir) is a glucagon-like peptide-1 receptor agonist that lowers blood sugar and reduces myocardial infarct size by improving endothelial cell function. However, its mechanism has not yet been clarified. Unfolded protein response (UPR) plays an important role in the pathogenesis of myocar...